Oral Mucositis Treatment Global Market Report 2025

The oral mucositis treatment market size has grown rapidly in recent years. It will grow from $1.77 billion in 2024 to $1.95 billion in 2025 at a compound annual growth rate (CAGR) of 10.2%. The growth during the historic period can be attributed to factors such as the increasing prevalence of cancer therapies, a rise in chemotherapy and radiation treatments, growing awareness of oral health complications, a higher demand for targeted therapies, and greater adoption of preventive and therapeutic treatments.

The oral mucositis treatment market size is expected to see rapid growth in the next few years. It will grow to $3.2 billion in 2029 at a compound annual growth rate (CAGR) of 13.1%. In the forecast period, growth is expected to be driven by a stronger focus on personalized medicine, a rise in the number of cancer patients, growing investment in innovative drug development, increasing healthcare expenditure in emerging markets, and more regulatory approvals for novel therapies. Key trends during this period include advancements in biologics for oral mucositis, innovation in combination therapies for improved efficacy, the development of non-invasive treatment options, advanced research in immunotherapy for mucositis, and innovation in personalized treatment regimens.

The growing use of chemotherapy is expected to drive the growth of the oral mucositis treatment market. Chemotherapy is a medical treatment that uses potent chemicals to destroy or inhibit the growth of cancer cells. The increased use of chemotherapy is due to its effectiveness in targeting cancer cells, providing patients with a higher chance of remission and better survival rates. Oral mucositis treatment alleviates pain, promotes healing, and prevents complications caused by chemotherapy, improving patient comfort during treatment. For example, according to the National Library of Medicine in May 2022, the number of patients requiring first-line chemotherapy is projected to rise from 9.8 million in 2022 to 15 million by 2040. As a result, the growing use of chemotherapy is driving the expansion of the oral mucositis treatment market.

Leading companies in the oral mucositis treatment market are focusing on developing advanced products that provide quick pain relief, aiming to improve patient comfort, enhance adherence to treatment, and support better recovery outcomes. Quick pain relief products refer to treatments that swiftly reduce pain and maintain relief over time without causing sharp, burning, or irritating sensations upon application. For example, in October 2024, Jaguar Health, a US-based company, launched Gelclair, an FDA-approved prescription product for managing and relieving oral mucositis pain. This innovative treatment features a protective gel action and soothing application, helping relieve pain and support oral function in cancer patients. Gelclair is highly effective, offering rapid pain relief and mucosal protection, making it an ideal treatment for oral mucositis in cancer patients, improving comfort and supporting oral function during therapy.

In July 2022, Solasia Pharma K.K., a Japan-based pharmaceutical company, acquired Camurus AB for an undisclosed amount. This acquisition allowed Solasia Pharma to enhance its oncology and pain management portfolio by integrating Camurus AB's innovative drug delivery technologies and pipeline products. Camurus AB, a pharmaceutical company based in Sweden, offers treatments for oral mucositis.

Major players in the oral mucositis treatment market are Sanofi S.A., Amgen Inc., Colgate-Palmolive Company, Aspen Pharmacare Holdings Limited, Swedish Orphan Biovitrum AB (Sobi), Sunstar Group, Norgine B.V., Alliance Pharma plc, Camurus AB, EUSA Pharma, Galera Therapeutics Inc., Enzychem Lifesciences Corporation, CANbridge Pharmaceuticals Inc., Jaguar Health Inc., Monopar Therapeutics Inc., EpicentRx Inc., Innovation Pharmaceuticals Inc., Oragenics Inc., Soleva Pharma LLC, Soligenix Inc.

North America was the largest region in the oral mucositis treatment market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in oral mucositis treatment report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the oral mucositis treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Oral mucositis treatment refers to therapies designed to prevent or manage inflammation and ulceration of the mucous membranes in the mouth, often caused by chemotherapy or radiation. These treatments aim to reduce discomfort, prevent infections, promote oral healing, and enhance the quality of life for cancer patients undergoing aggressive therapies.

The primary types of oral mucositis treatments include pharmaceutical drugs, laser therapy, cryotherapy, oral rinses and mouthwashes, and other treatment modalities. Pharmaceutical drugs are substances used to diagnose, treat, or prevent diseases by influencing the body's functions or processes. These can be administered through various routes, such as oral, intravenous, subcutaneous, topical, and others. They are indicated for specific causes, including chemotherapy-induced oral mucositis, radiotherapy-induced oral mucositis, and other related conditions. These medications are distributed through multiple channels, including online pharmacies, retail pharmacies, hospital pharmacies, and direct sales. The medications are used by a wide range of end-users, such as hospitals, homecare settings, ambulatory surgical centers, and long-term care facilities.

The oral mucositis treatment market research report is one of a series of new reports that provides oral mucositis treatment market statistics, including the oral mucositis treatment industry global market size, regional shares, competitors with the oral mucositis treatment market share, detailed oral mucositis treatment market segments, market trends, and opportunities, and any further data you may need to thrive in the oral mucositis treatment industry. This oral mucositis treatment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The oral mucositis treatment market consists of revenues earned by entities by providing services such as pain management, and antimicrobial treatments. The market value includes the value of related goods sold by the service provider or included within the service offering. The oral mucositis treatment market also includes sales of topical anesthetics, and anti-inflammatory agents. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.